AC Immune SA reported first-half 2026 financial results showing total revenue of CHF 16.2 million, driven by an CHF 11.0 million upfront payment and milestone from a Lilly agreement amendment and CHF 5.2 million in Takeda contract revenues. The company incurred a net loss of CHF 12.9 million, a significant improvement from the CHF 40.2 million loss in the prior year period, aided by reduced R&D expenses of CHF 22.2 million following a September 2025 reorganization. Liquidity stood at CHF 75.4 million as of June 30, 2026, providing funding through Q4 2027. The filing also announced that Dr. Andrea Pfeifer retired as CEO and Martin Zügel was appointed interim CEO. AC Immune is a clinical-stage biopharmaceutical company developing active immunotherapies and small molecules for neurodegenerative diseases.
